Integrichain Announces Close Of Nordic Capital Majority Investment
12/19/23, 4:04 PM
Location
Investors
Accel Kkr, Nordic Capital
IntegriChain today announced the close of an investment agreement whereby Nordic Capital has acquired the majority stake in IntegriChain. IntegriChain's integrated ICyte Platform helps pharma manufacturers connect the commercial, financial, and operational dimensions of drug commercialization, access, and profitability. Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Pharma, acquired the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.
Company Info
Location
philadelphia, pennsylvania, united states
Additional Info
IntegriChain helps Pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. We are doing this by building Pharma’s data-driven commercialization platform – from strategy to operational execution. Our unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net.